, Phe 89 and Leu 709 on insulin induced receptor autophosphorylation. They had no effect on the maximal response to insulin but produced an increase in the EC50 commensurate with their effect on the affinity of the receptor for insulin.
INTRODUCTION
The initiating event in the insulin signaling cascade is the binding of insulin to a specific plasma membrane receptor. This interaction has been extensively studied and has been found to be extremely complex(for review see ref. (1)). Scatchard plots (2) of equilibrium binding data are concave and curvilinear, suggesting heterogeneity of ligand binding sites, negatively cooperative site-site interactions or a combination of both (1) . These properties and high affinity interactions with insulin are dependent on the dimeric structure of the receptor; insulin binds non-cooperatively to a single population of binding sites in the monomeric receptor (3) (4) (5) . The stoichiometry of binding to the native receptor appears to be one insulin molecule to one receptor dimer (6) . The secreted recombinant extracellular domain of the receptor exhibits similar properties to those of the receptor monomer and has a stoichiometry of two insulin molecules to one receptor dimer (6;7) .
A number of hypothetical models of insulin-receptor interactions have been proposed to explain these findings (7) (8) (9) . The model that best explains the experimental findings is that of De Meyts (1) . This proposes that insulin has two topographically distinct receptor binding sites and that the receptor has two topographically distinct insulin binding sites per monomer. In this model insulin binds asymmetrically to the insulin dimer with each of its binding sites contacting its cognate receptor site on a separate monomer. While the detailed structural basis of this model has yet to be elucidated, the structure-function relationships of the insulin molecule and the receptor have been extensively studied and provide support for the essentials of the model.
Insulin is a 6Kd globular protein with disulfide linked A and B chains (for review see ref. (10) ). The consensus of published studies is that it has a receptor binding site composed of Gly A1, Ile A2, Val A3, Gln A5, Tyr A19, Val B12, Tyr B16, Gly B23, Phe B24, Phe B25 and Tyr B26 (1;10). However hagfish insulin, in which these residues and the tertiary structure of the molecule are conserved (11) , displays anomalous receptor binding behavior (11;12) , suggesting that other residues outside this region might also be involved in receptor interactions. This is supported by the finding that two recombinant insulin analogues with substitutions in residues located on the opposite side of the molecule, Leu A13 to Ser and Leu B17 to Gln, exhibited similar receptor binding behavior to hagfish insulin (7;8).
The structure and structure-function relationships of the insulin receptor are less well documented. It is a dimeric trans-membrane protein: see ref.
(1) for review. Each monomer consists of disulfide linked α and β subunits. The α subunits are wholly extracellular and contain the ligand binding site(s) and the β subunit has an extracellular component, a single transmembrane helix and an intracellular component with tyrosine kinase catalytic activity. The structure of the Nterminius of the homologous IGF-I receptor has been determined (13); amino acids 1-460 in IGFR, corresponding to amino acids 1-470 of IR. It consists of two globular β helical domains (L1 and L2) flanking a cysteine rich domain (CRD). Comparative homology modeling suggests the remainder of the extracellular domain to be composed of three type 3 fibronectin repeats FnIII0, FnIII1 and FnIII2 (14) (15) (16) . FnIII1 is atypical because it contains a 120 amino acid insert domain of indeterminate structure (15) . Affinity labeling studies, studies with chimeric receptors and the epitopes of anti-receptor antibodies which inhibit insulin binding strongly suggest the each receptor monomer contains two topologically discrete ligand binding sites (17) (18) (19) (20) (21) (22) .
We have characterized a binding site of the secreted recombinant insulin receptor, using alanine scanning mutagenesis (17;18;23-25) . This is composed of two functional epitopes, one located on the base of the L1 domain and the other at the C-terminus of the α  subunit. As discussed above, the secreted recombinant receptor exhibits anomalous binding properties, suggesting monovalent insulin binding (7) . In order to evaluate the function of this binding site in the holo-receptor , i.e. where there is bivalent binding, we have expressed alanine mutants of the residues that comprise this functional epitope as full length proteins. We found that all mutations with the exception of two residues which were minor contributors to the epitope of the secreted receptor impaired binding. All hot spot residues were conserved but an additional residue was present in the holo-receptor hot spot. In addition a number of residues which we had previously shown to vary in their contributions to the free energy of binding of the two isoforms of the secreted receptor also differed in their contribution to the free energy of binding of the holo-receptor. In three selected mutants, the effects of the mutations on the sensitivity of insulin regulated receptor auto-phosphorylation were commensurate with their effects on affinity for insulin.
EXPERIMENTAL PROCEDURES
General procedures-All molecular biological procedures including agarose gel electrophoresis, restriction enzyme digestion, ligation, bacterial transformation and DNA sequencing were performed by standard methods (26) . Restriction and modifying enzymes were from New England Biolabs. Recombinant human insulin was from NovoNordisk A/S. HPLC-purified monoiodinated [ 125 I-TyrA14] insulin was from Amersham. Protease inhibitors were from Roche Molecular Biochemicals. PEAK Rapid cells were purchased from Edge Biosystems (Gaithersburg, MD). Medium and serum for tissue culture were from Cellgro. The mammalian expression vector pcDNA3.Zeo+ was from InVitrogen. Coding sequences for a triple repeat of the AU5 epitope tag (TDFYLK) was introduced between the BamHI and XbaI sites of the pcDNA3.Zeo+ polylinker by cassette mutagenesis. The cDNA for the insulin receptor was as previously described (27) . It was modified for sub-cloning into the epitope tag expression vector by elimination of the existing Bam HI site by a silent mutation and introduction of an in frame Bam HI site encoding a Gly-Ser linker at the 3' end of the coding sequence by site-directed mutagenesis.
Monoclonal anti-AU5 IgG was purchased from Covance.
Construction of receptor mutants-Alanine mutations of the cDNA encoding the recombinant secreted receptor extra-cellular domain have been described previously (23) (24) (25) . These were used to generate full length epitope-tagged mutants of the full length receptor by standard sub-cloning techniques.
Expression of Receptor cDNAs-Plasmid DNA for transfection was prepared as previously described (28) . The receptor cDNAs were expressed transiently in PEAK rapid cells using Transit 293 (Mirus) according to the manufacturers' directions. Cells were harvested by lysis in 0.15M NaCl, 0.1M Tris pH 8 containing 1%Triton X-100 and protease inhibitor cocktail 72h posttransfection and an enriched glycoprotein fraction was obtained by wheat germ agglutinin affinity chromatography (29) . These were stored at -80C until assay.
Receptor Binding Assays-Insulin competitive receptor binding assays were performed by a modification of the microtiter plate antibody capture assay that we have described previously (24) . Microtiter strip plates (Nunc Maxisorb) were incubated overnight at 4C with AU5 IgG (100µl/well of 40mg/ml in PBS). Washing, blocking, receptor binding and competitive binding assays with labeled and unlabeled peptides were performed as described. Binding data were analyzed by a 2 site sequential model (8;30) . Receptor Autophosphorylation-Insulin stimulated receptor tyrosine autophosphorylation was evaluated with a modification of a time resolved fluorescence assay of insulin-like growth factor receptor auto-phosphorylation (31;32). Concentrations of mutant and wild type receptors in enriched glycoprotein fractions from transfected cell lysates were determined by receptor ELISA (24) . Equal concentrations of mutant and wild type receptors were incubated with varying concentrations of insulin in 0.1ml 0.15MNaCl, MgCl2 10mM, HEPES 25mM pH 7.8 , Triton X-100 0.05% (v/v) for 2h at 25C. Autophosphorylation was initiated by addition of Na2V04 and MgCl2 to final concentrations of 2mM and 10mM respectively. The reaction was stopped after 20 minutes by the addition of EDTA and EGTA to final concentrations of 25mM. The reaction mixture was then transferred to Delfia micro-titer assay plates (Perjkin-Elmer) coated with anti-AU5 IgG and incubated overnight at 4C to immobilize insulin receoptor. After washing with PBS Tween-20 0.02%, receptors were incubated with Europium labeled PY20 (PerkinElmer) according to the manufacturers directions. After washing, phosphotyrosine containing receptor was quantitated by time resolved fluorescence using a Victor 3 (Perkin Elmer) plate reader. EC50s (concentrations of insulin producing half maximal response) were obtained from the dose response data by non linear least squares analysis using Prism (GraphPad Software).
RESULTS
Insulin Binding-We have previously characterized the functional epitopes of the secreted recombinant insulin receptor extracellular domain by alanine scanning mutagenesis (23) (24) (25) . In order to determine significance of these epitopes for insulin binding in a physiological context, we sub-cloned the alanine mutations used to characterize them into the full length B isoform receptor cDNA tagged at its 3' end with the coding sequence for a triple repeat of the AU-5 epitope tag. (23) (24) (25) .
In order to characterize the equilibrium binding properties of the mutant receptors, detergent lysates of transfected cells were depleted of receptor pre-cursor by wheat germ agglutinin affinity chromatography (29) . Insulin equilibrium binding assays were then performed on receptor isolated from the resulting glycoprotein fractions and dissociation constants and IC50s were determined by computerized curve fitting using a two site sequential model as described under "Methods". For wild type insulin receptor, Kd1, the dissociation constant of the high affinity component of binding, was 0.03 ± 0.001 nM ; Kd2, the dissociation constant of the low affinity component of binding, was 0.4 ± 0.01 nM and the IC50 was 0.09 ± 0.01 nM (mean ± SEM, n=8; Table 1 ). These binding properties differ significantly from those of the secreted recombinant insulin receptor determined under similar experimental conditions. With this form of the receptor, insulin binds to a single population of binding sites with a lower affinity, Kd = 2.1nM, (24) . This is consistent with the findings reported in other studies (7;17) .
The dissociation constants and IC50s of alanine mutants of residues in the L1 domain and in the C-terminus of the α -subunit are summarized in Tables 1A and 1B For all receptors studied, the dose response curve for auto-phosphorylation was bell-shaped ( Fig. 1 ). Insulin produced a maximal 4.4 to 6.5 stimulation of auto-phosphorylation and there were no significant differences between receptors (data not shown). The mutant receptors produced right shifts in the dose response curve (Figure 1 ) and the EC50s for receptor autophosphorylation corresponded reasonably well with the IC50s for insulin binding (Table 2) .
DISCUSSION
In order to compare the relative impact of the alanine mutations on the affinities of the full length receptor and the secreted recombinant receptor extra-cellular domain, the ratios of the IC50 of the mutant to the wild type IC50 for each mutation were compared for each type of receptor (Fig 1) , which has no impact on the affinity of the secreted receptor inactivates the full length receptor. Quantitatively similar changes in affinity in both forms of the receptor (4 to10-fold) result from alanine mutations of Gln Thus, consistent with previous findings, we found that the affinity of the native insulin receptor for insulin is higher than that of the secreted recombinant receptor and its binding kinetics are more complex (7;17) . While the functional epitopes of the equivalent ligand binding site of both forms of receptor are similar, certain amino acids appear to make significantly different contributions the free energy of binding of each form of the receptor. It is worth considering these findings in the context of current models of insulin/receptor interactions. Both De Meyts and Schaffer have proposed similar bivalent mechanisms of insulin binding to the receptor (7;8) . Both propose that there are two distinct receptor binding sites on the insulin molecule and that there are two distinct insulin binding sites on each subunit(1;7). Insulin first binds to one site on one α subunit and then cross-links the two heterodimers by binding to the non-equivalent site on the second subunit, generating the high affinity component of the receptor interaction. Binding of a second insulin molecule in this manner disrupts the cross-linking of the first and accelerates its dissociation (negative cooperativity), giving rise to the complex binding behavior exhibited by insulin interactions with the full length receptor. In contrast, in the recombinant secreted receptor and the isolated heterodimer, it is postulated that insulin only binds to the site with higher affinity and hence this interaction displays a lower affinity than that of the native receptor and simple binding kinetics. From the data presented by Shaffer (7), it is apparent that the affinity of this site is very much greater than that of the other. Thus it would be expected mutations producing changes in the affinity of this binding site for insulin, in the recombinant secreted receptor would also produce comparable changes in affinity of the holoreceptor. In general, this appears to be the case. Further this model would also suggest that alanine mutations compromising the higher affinity site, i.e. the binding site of the secreted recombinant receptor would have similar effects on the high and low affinity components of insulin binding in the full length receptor as is generally observed in the present study.
The sequential binding mechanism may also provide an explanation for the differences in the functional epitopes observed for the two forms of the receptor. Insulin has been observed to have varying conformations in different crystallographic and NMR solution structures (33;34) . Thus it is possible that the initial binding event in the full length receptor may lead to a change in its conformation from that in solution thus producing the differences in effects of the alanine mutations from those observed with the secreted receptor. Further previous studies from this laboratory comparing the functional epitopes of the A and B isoforms of the receptor have provided evidence for plasticity in the conformation of the ligand binding site of the receptor (24) . It is perhaps significant that the mutations which produce the most divergent effects in the full length and secreted receptor involve those residues that are most divergent in the functional epitopes of the A and B isoforms of the secreted receptor (24) .
We also compared the effects of mutations of Asn 15 , Gln 34 and Phe 89 on insulin induced receptor auto-phosphorylation. The dose-response curve for auto-phosphorylation was bell-shaped for all receptors. Such bell-shaped curves are indicative of bivalent binding mechanisms involving ligand cross-linking of binding sites (1) . There were no significant differences in the maximal response to insulin, indicating that the coupling between ligand binding and the conformational changes resulting in activation of the receptor tyrosine kinase catalytic activity is intact in these mutants. This further confirms the structural integrity of the mutants. However these mutations did result in shifts of the concentration dependence of insulin regulated receptor auto-phosphorylation, which correlated reasonably well with the changes in affinity for insulin. This is consistent with the results of studies of the biological activities of insulin analogues which bind to this site, in which it was found that changes in potency correlated with changes in affinity for the receptor (35) .
In summary we have demonstrated that alanine mutations of amino acids in the functional epitope of the secreted recombinant receptor largely have similar effects on the affinity of the full length receptor for insulin. Further, we have shown that selected mutations cause changes in the insulin sensitivity of receptor proportional to their effects on affinity for insulin.
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The abbreviations used are: [125I-Tyr A14] insulin, insulin radio-iodinated at Tyrosine 14 of the A polypeptide chain of insulin. Figure 1 : Insulin regulated auto-phosphorylation of mutant receptors. 293 PEAK cells were transiently transfected with insulin receptor cDNAs. Seventy two hours post-transfection, cells were harvested by detergent lysis and enriched glycoprotein fractions of cell lysates were prepared by wheat germ agglutinin chromatography (29) . Insulin receptors were autophosphorylated in the presence of varying concentrations of insulin as described under "Experimental Procedures". Results are expressed as % maximal stimulation and represent the mean S.E.M. of three independent experiments. The mutants are designated by the amino acid being mutated in single-letter code, followed by the number indicating its position in the insulin receptor sequence, followed by alanine. Table 1 were expressed as the ratio of the IC50 of the alanine mutant receptor to IC50 of the wild type receptor (IC50 MUT/ IC50 WT). Data for the secreted receptor (sIR) were taken from ref. (24) . Results represent the mean of 4 independent experiments for each receptor. Amino acids mutated to alanine are designated by the single letter code. Those mutants with an affinity for insulin that was too low to be determined accurately were arbitrarily assigned a value for IC50MUT/ IC50 WT of 100. Table 2 Comparison of EC50s for receptor autophosphorylation and IC50s for insulin of mutant receptors. EC50s for insulin regulated receptor auto-phosphorylation were obtained by non-linear least squares analysis of the data in Figure 1 . Data for relative IC50s are from 
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